UCB
UCB
Performance
About UCB
UCB is a global biopharmaceutical leader focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. The company operates worldwide with a focus on research, development, and patient support in areas such as epilepsy, Parkinson’s-related disorders, and autoimmune diseases. Based in Belgium, UCB emphasizes innovative science and patient-centric programs through its UCBCares initiative and ongoing clinical studies and publications.
Recent News
UCB to Acquire Maker of Antibody Treatments for Autoimmune Diseases
Candid Therapeutics Acquired by UCB for up to $2.2 Billion
Vimseltinib
Havas Red Appoints Erin Sing to Executive Director, Melbourne Role
UCB to Acquire Candid Therapeutics for $2 B, Adding T‑Cell Engager Platform to Immunology Portfolio
Pharma and Biotech M&As 2026 Deal Watcher
AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis
UCB Bets $2 Billion on Candid's T Cell Engager Ambitions
STAT+: Pharmalittle: We’re Reading About an Abortion Pill Controversy, Another UCB Deal, and More News
CMS's Medicare Price Negotiations Start Round Three
Top Biotech Deals in March 2026
UCB to Acquire Neurona Therapeutics for Up to $1.15 Billion, Boosting Epilepsy Portfolio
Leqembi Starts to Deliver for Eisai and Biogen
PCI Adds US Sterile Fill/Finish Capabilities Through $1B Global Expansion Drive
Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD
The BioPharm Brief: RNA Editing, Liver Safety, Joint Gains
UCB to Acquire Neurona Therapeutics for $650M, Adding Regenerative Epilepsy Asset
Miles Gerson, Sofia Guerra Among VCs Landing New Roles
VIDEO: ‘New Era of Oral Therapies’ on Horizon in Psoriasis
GHO, CBC Merge to Create Largest Healthcare Investment Firm
Bimekizumab Demonstrates Superiority Over Risankizumab in Psoriatic Arthritis Trial
UCB Reports P-III (BE BOLD) Trial Data on Bimzelx in Active Psoriatic Arthritis
‘Orchestra of Therapies’ Required for Most SSc Patients
Xenon’s Azetukalner Clears Phase III Hurdle in Focal Epilepsy, Eyes FDA Filing
Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics
‘Over and Above’ Responses Seen with Envudeucitinib for Plaque Psoriasis
Drug Trials Snapshots: BIMZELX
CSL Plans $1.5B Expansion of Illinois Plasma Therapy Manufacturing Facility
Zelestra Brings Spanish 162MW Solar PV Portfolio Online
UCB Bags First EU Approval for Rare Genetic Disease TK2d
2025 Novel Small Molecule FDA Drug Approvals